422 related articles for article (PubMed ID: 16265658)
1. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
[TBL] [Abstract][Full Text] [Related]
2. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.
Rütten H; Pop LA; Janssens GO; Takes RP; Knuijt S; Rooijakkers AF; van den Berg M; Merkx MA; van Herpen CM; Kaanders JH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):923-9. PubMed ID: 21095074
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
8. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
[TBL] [Abstract][Full Text] [Related]
9. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
[TBL] [Abstract][Full Text] [Related]
10. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
11. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
Lau H; Phan T; Mackinnon J; Matthews TW
Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
[TBL] [Abstract][Full Text] [Related]
13. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
[TBL] [Abstract][Full Text] [Related]
14. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
19. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
